Juan P. Alderuccio
@JuanAlderuccio
Hematologist-Oncologist | Lymphoma Physician @SylvesterCancer | @umiamimedicine I Member @ASH_hematology Committee on Educational Affairs & Media Experts
Published in @BloodJournal today, our approach to secondary CNS involvement by aggressive lymphomas Here is a free access link authors.elsevier.com/a/1i8Pv1UYwjRKH ashpublications.org/blood/article-…
Do you have advanced #cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: bit.ly/ComboMATCH
The FDA-AACR Oncology Educational Fellowship provides early-career scientists and clinicians with an opportunity to learn more about drug development and the regulatory review process from @FDAOncology and AACR experts. Apply by Aug 1: brnw.ch/21wUhUu #AACRSciencePolicy
Check out the newest @ASH_hematology #ASHImageBank challenge in the current issue of The Hematologist by @amayallorente The images are mind blowing!!! A brilliant teaching case. #hemepath @BloodPortfolio ashpublications.org/thehematologis…
Catch up on the latest breakthroughs in #HemOnc with our expert-led Post-#EHA2025 & #18ICML Highlights webinars @EHA_Hematology @icmlugano The #Lymphoma session will be chaired by Dr Caron Jacobson & moderated by @CwynKate & Dr John Kuruvilla REGISTER 👉 us06web.zoom.us/webinar/regist…
Our group's latest publication demonstrates the correlation between PET/CT-derived body composition and outcome in DLBCL. #DeepLearning #lymsm #lymphoma @SylvesterCancer @DrTracyECrane @CraigMoskMD @UMiamiHealth ascopubs.org/doi/10.1200/CC…
Delighted to share our review paper on the treatment of MZL published @BloodPortfolio. Great collaboration with @ArielaNoyMD @MSK_DeptOfMed @MSKCancerCenter @SylvesterCancer @UMiamiHealth ashpublications.org/blood/article-…
Amazing meeting today! #ASH #Fight4Hematology
ASH Committee on Communications Summer 2025 meeting complete! Energized to strengthen our Fight4Hematology campaign & advocacy efforts protecting federal funding for hematology research. The future of hematology care depends on continued innovation. #ASH #Fight4Hematology
This year marks a milestone in the Lymphoma Research Foundation's journey: three decades of advancing lymphoma research, empowering patients, and building a compassionate community united by resilience, determination, and unwavering hope: lymphoma.org/30years #lymphoma30
I'm looking forward to participating in @karmanoscancer Annual Lymphoma Symposium and discussing recent advances in CNS lymphomas. #lymphoma #lymsm
Please join us at the 7th Annual Lymphoma Symposium organized on August 2, 2025. Outstanding speakers will review the latest data and spark thought provoking discussions. Registration link: karmanos.org/karmanos/lymph…
Big thanks to a great team behind this novel & ambitious study @Jessica_Okosun @CwynKate @graham_mcilroy @MartinezCalleMD #jeffsmith #bethphilips et al @CRCTU_Haem_Team @CRCTU #TAPnetwork @act4patients @CureLeukaemia @BloodCancer_Res
At #18ICML, @ProfChrisPFox of @nottmhospitals shared the results of cohort one of the PRiZM+ platform study, in which patients with R/R primary CNS #lymphoma were treated with zanubrutinib monotherapy.🩸 Watch here: 🎥 ow.ly/ZqlI50WfTcN #LYMsm #CTSM #HemOnc #ICML2025
I am excited to announce that we @umiamimedicine and @MiamiProject, have successfully implanted our first patient, RJ, as part of @neuralink's PRIME Study! Thank you @elonmusk for revolutionizing therapies for our patients!
🚨🚨🚨 📣We have published our 100th paper! ow.ly/tHaG50Wh38y 🎉🎉🎉
Top Oncologists from 18th International Conference on Malignant Lymphoma (@icmlugano 2025). Explore data and insights #ICML2025: t.ly/dz8T1 #LARVOL #Hematology #Lymphoma #CancerResearch #Oncology #CancerData #OncologyInsights #18ICML | @graham74GC | @majorajay |…
Here are the top 10 trials from the 18th International Conference on Malignant Lymphoma (@icmlugano 2025). Explore data and insights #ICML2025: t.ly/dz8T1 #LARVOL #Hematology #Lymphoma #CancerResearch #Oncology #CancerData #OncologyInsights #18ICML | @graham74GC |…
CONGRESS | #18ICML | PRESENTATION Kate Cwynarski @CwynKate @uclh presents 7-year follow-up results from the phase II MARIETTA trial of multi-agent chemotherapy with MATRix and R-ICE followed by TT-ASCT in patients with SCNSL (N = 75). Long-term follow-up results demonstrate…
Impressive results and excellent presentation by @JenCrombieMD @DanaFarber @SylvesterCancer
Glofit joins frontline fight in DLBCL (IPI ≥ 2). 6 cycles pola-R-CHP, Glofit added after cycle 2: 🔸ORR 95%, CR 90% 🔸12-mo PFS 95%, OS 98% 🔸95% MRD– at EOT (ClonoSEQ, of evaluable) 🔸Grade 1 CRS in 10%, no dex premed 6 pts converted MRD+ ➝ MRD– after Glofit. #18ICML #lymsm
CONGRESS | #18ICML | POSTER Izidore S Lossos @SylvesterCancer shares an updated analysis from a phase II study of loncastuximab for the treatment of R/R marginal zone lymphoma. ORR was 85% with a CR rate of 69%, median duration of CR was 13.7 months, 12-month PFS 92.9% Safety was…
Dr. Emanuele Zucca is really a lymphoma legend and trailblazer! The IELG has truly transformed our understanding, prognosis and tx strategies for EN B cell NHL. The power of academic collaboration! #18ICML #lymsm
Lonca + glofi in R/R LBCL @JuanAlderuccio #18ICML - 41 pts, 55% IPI 3+, 20% prior CAR - no G5 TEAEs, 6 dc'd d/t AEs - 1 G3 CRS, no G3+ ICANS - ORR 93%, DOR NR (25/26 CRs remained in CR) Looking forward to longer f/u. #lymsm
CONGRESS | #18ICML | PRESENTATION Juan Pablo Alderuccio @JuanAlderuccio @SylvesterCancer presents the initial results from LOTIS-7, evaluating loncastuximab tesirine plus glofitamab in patients with R/R #DLBCL. ORR across all dose levels 93.3%, with a CR rate of 86.7%. Most…